Skip to menu Skip to content Skip to footer
Dr John Lee
Dr

John Lee

Email: 
Phone: 
+61 7 336 52384

Overview

Background

Dr Lee is a mid-career researcher with training in neuroscience, and additional experience in pharmacology and immunity. He completed his Ph.D. at the University of Queensland (UQ) in 2014 and continued his post-doctoral research studies in neuroinflammation and neurodegenerative diseases. He is currently a Senior Research Fellow and Group Leader at UQ's School of Biomedical Sciences, where he focusses on innate immune and inflammatory pathways including the complement system and inflammasomes in motor neuron disease (amyotrophic lateral sclerosis), Huntington’s disease, and Parkinson’s disease. Dr Lee’s research has demonstrated the therapeutic potential of multiple anti-inflammatory drugs targeting innate immune-mediated neuroinflammation to reduce neuronal cell death in animal models of neurodegenerative disease. He is also interested in the links between the immune system, stress response, and energy metabolism in neurodegeneration.

Availability

Dr John Lee is:
Available for supervision
Media expert

Qualifications

  • Bachelor (Honours) of Science (Advanced), The University of Queensland
  • Doctor of Philosophy, The University of Queensland

Research interests

  • Neuroimmunology in neurodegenerative diseases

    We explore the involvement of innate immune cells in the pathogenesis of MND, HD, and PD to identify potential therapeutic targets. By elucidating the mechanisms underlying neuroinflammation, we aim to develop interventions that halt or slow disease progression.

  • Immunometabolism in neuroinflammation

    Our group investigates the metabolic capacity of innate immune cells within the central nervous system, including neutrophils, macrophages, microglia, and astrocytes. By understanding how alterations in cellular metabolism impact immune function, we aim to uncover new strategies for modulating neuroinflammatory responses.

  • Immune system – Stress response crosstalk

    We explore the intricate relationship between the immune system and the stress response, particularly its implications in neuropsychiatric disorders. By unravelling the molecular mechanisms underlying this crosstalk, we aim to identify new therapeutic targets for conditions such as depression, anxiety, and post-traumatic stress disorder (PTSD).

  • Immunosenescence and Neurological Aging

    Our group investigates the link between the immune system and aging within the context of neurological health. By studying age-related changes in immune function and their impact on brain health, we aim to develop interventions that promote healthy aging and mitigate age-related neurological disorders.

Works

Search Professor John Lee’s works on UQ eSpace

71 works between 2009 and 2024

21 - 40 of 71 works

2021

Journal Article

In vivo pharmacodynamic method to assess complement C5a receptor antagonist efficacy

Cui, Cedric S., Kumar, Vinod, Gorman, Declan M., Clark, Richard J., Lee, John D. and Woodruff, Trent M. (2021). In vivo pharmacodynamic method to assess complement C5a receptor antagonist efficacy. ACS Pharmacology and Translational Science, 5 (1) acsptsci.1c00227, 41-51. doi: 10.1021/acsptsci.1c00227

In vivo pharmacodynamic method to assess complement C5a receptor antagonist efficacy

2021

Journal Article

Unexpected off-target activities for recombinant C5a in human macrophages

Li, Xaria X., Gorman, Declan M., Lee, John D., Clark, Richard J. and Woodruff, Trent M. (2021). Unexpected off-target activities for recombinant C5a in human macrophages. Journal of Immunology, 208 (1), 133-142. doi: 10.4049/jimmunol.2100444

Unexpected off-target activities for recombinant C5a in human macrophages

2021

Journal Article

Development of synthetic human and mouse C5a: application to binding and functional assays in vitro and in vivo

Gorman, Declan M., Li, Xaria X., Payne, Colton D., Cui, Cedric S., Lee, John D., Rosengren, K. Johan, Woodruff, Trent M. and Clark, Richard J. (2021). Development of synthetic human and mouse C5a: application to binding and functional assays in vitro and in vivo. ACS Pharmacology and Translational Science, 4 (6) acsptsci.1c00199, 1808-1817. doi: 10.1021/acsptsci.1c00199

Development of synthetic human and mouse C5a: application to binding and functional assays in vitro and in vivo

2021

Journal Article

Development of Potent and Selective Agonists for Complement C5a Receptor 1 with In Vivo Activity

Gorman, Declan M., Li, Xaria X., Lee, John D., Fung, Jenny N., Cui, Cedric S., Lee, Han Siean, Rolfe, Barbara E., Woodruff, Trent M. and Clark, Richard J. (2021). Development of Potent and Selective Agonists for Complement C5a Receptor 1 with In Vivo Activity. Journal of Medicinal Chemistry, 64 (22) acs.jmedchem.1c01174, 16598-16608. doi: 10.1021/acs.jmedchem.1c01174

Development of Potent and Selective Agonists for Complement C5a Receptor 1 with In Vivo Activity

2021

Journal Article

Intrinsic bias at non-canonical, β-arrestin-coupled seven transmembrane receptors

Pandey, Shubhi, Kumari, Punita, Baidya, Mithu, Kise, Ryoji, Cao, Yubo, Dwivedi-Agnihotri, Hemlata, Banerjee, Ramanuj, Li, Xaria X., Cui, Cedric S., Lee, John D., Kawakami, Kouki, Maharana, Jagannath, Ranjan, Ashutosh, Chaturvedi, Madhu, Jhingan, Gagan Deep, Laporte, Stéphane A., Woodruff, Trent M., Inoue, Asuka and Shukla, Arun K. (2021). Intrinsic bias at non-canonical, β-arrestin-coupled seven transmembrane receptors. Molecular Cell, 81 (22), 4605-4621.e11. doi: 10.1016/j.molcel.2021.09.007

Intrinsic bias at non-canonical, β-arrestin-coupled seven transmembrane receptors

2021

Journal Article

The emerging role of complement in neuromuscular disorders

Lee, John D. and Woodruff, Trent M. (2021). The emerging role of complement in neuromuscular disorders. Seminars in Immunopathology, 43 (6), 817-828. doi: 10.1007/s00281-021-00895-4

The emerging role of complement in neuromuscular disorders

2021

Journal Article

The concise guide to pharmacology 2021/22: G protein‐coupled receptors

Alexander, Stephen PH, Christopoulos, Arthur, Davenport, Anthony P, Kelly, Eamonn, Mathie, Alistair, Peters, John A, Veale, Emma L, Armstrong, Jane F, Faccenda, Elena, Harding, Simon D, Pawson, Adam J, Southan, Christopher, Davies, Jamie A, Abbracchio, Maria Pia, Alexander, Wayne, Al‐hosaini, Khaled, Bäck, Magnus, Barnes, Nicholas M., Bathgate, Ross, Beaulieu, Jean‐Martin, Bernstein, Kenneth E., Bettler, Bernhard, Birdsall, Nigel J.M., Blaho, Victoria, Boulay, Francois, Bousquet, Corinne, Bräuner‐Osborne, Hans, Burnstock, Geoffrey, Caló, Girolamo ... Ye, Richard D. (2021). The concise guide to pharmacology 2021/22: G protein‐coupled receptors. British Journal of Pharmacology, 178 (S1), S27-S156. doi: 10.1111/bph.15538

The concise guide to pharmacology 2021/22: G protein‐coupled receptors

2021

Journal Article

Complement peptide receptors in GtoPdb v.2021.3

Cianciulli, Antonia, Coulthard, Liam, Hawksworth, Owen, Lee, John D., Li, Xaria X., Mitolo, Vincenzo, Monk, Peter, Panaro, Maria A. and Woodruff, Trent M. (2021). Complement peptide receptors in GtoPdb v.2021.3. IUPHAR/BPS Guide to Pharmacology CITE, 2021 (3), 1-13. doi: 10.2218/gtopdb/f5/2021.3

Complement peptide receptors in GtoPdb v.2021.3

2021

Journal Article

Glucose clearance and uptake is increased in the SOD1 G93A mouse model of amyotrophic lateral sclerosis through an insulin‐independent mechanism

McDonald, Tanya S., Kumar, Vinod, Fung, Jenny N., Woodruff, Trent M. and Lee, John D. (2021). Glucose clearance and uptake is increased in the SOD1 G93A mouse model of amyotrophic lateral sclerosis through an insulin‐independent mechanism. The FASEB Journal, 35 (7) e21707, e21707. doi: 10.1096/fj.202002450r

Glucose clearance and uptake is increased in the SOD1 G93A mouse model of amyotrophic lateral sclerosis through an insulin‐independent mechanism

2021

Journal Article

Complement: a global immunometabolic regulator in amyotrophic lateral sclerosis

Lo, Martin W. and Lee, John D. (2021). Complement: a global immunometabolic regulator in amyotrophic lateral sclerosis. Neural Regeneration Research, 16 (6), 1210-1211. doi: 10.4103/1673-5374.300441

Complement: a global immunometabolic regulator in amyotrophic lateral sclerosis

2021

Journal Article

The “C3aR Antagonist” SB290157 is a partial C5aR2 agonist

Li, Xaria X., Kumar, Vinod, Clark, Richard J., Lee, John D. and Woodruff, Trent M. (2021). The “C3aR Antagonist” SB290157 is a partial C5aR2 agonist. Frontiers in Pharmacology, 11 591398, 591398. doi: 10.3389/fphar.2020.591398

The “C3aR Antagonist” SB290157 is a partial C5aR2 agonist

2021

Journal Article

Chemical synthesis and characterisation of the complement C5 inhibitory peptide zilucoplan

Gorman, Declan M., Lee, John, Payne, Colton D., Woodruff, Trent M. and Clark, Richard J. (2021). Chemical synthesis and characterisation of the complement C5 inhibitory peptide zilucoplan. Amino Acids, 53 (1), 143-147. doi: 10.1007/s00726-020-02921-5

Chemical synthesis and characterisation of the complement C5 inhibitory peptide zilucoplan

2021

Journal Article

Clinical and electrophysiological examination of pinch strength in patients with amyotrophic lateral sclerosis

Lee, John D., Heshmat, Saman, Heggie, Susan, Thorpe, Kathryn A., McCombe, Pamela A. and Henderson, Robert D. (2021). Clinical and electrophysiological examination of pinch strength in patients with amyotrophic lateral sclerosis. Muscle and Nerve, 63 (1) mus.27111, 108-113. doi: 10.1002/mus.27111

Clinical and electrophysiological examination of pinch strength in patients with amyotrophic lateral sclerosis

2020

Journal Article

TDP-43 Puts the STING in ALS

Lee, John D. and Woodruff, Trent M. (2020). TDP-43 Puts the STING in ALS. Trends in Neurosciences, 44 (2), 81-82. doi: 10.1016/j.tins.2020.12.001

TDP-43 Puts the STING in ALS

2020

Journal Article

Complement peptide receptors (version 2020.5) in the IUPHAR/BPS Guide to Pharmacology Database

Cianciulli, Antonia, Coulthard, Liam, Hawksworth, Owen, Lee, John D., Li, Xiang X., Mitolo, Vincenzo, Monk, Peter, Panaro, Maria A. and Woodruff, Trent M. (2020). Complement peptide receptors (version 2020.5) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide to Pharmacology CITE, 2020 (5). doi: 10.2218/gtopdb/f5/2020.5

Complement peptide receptors (version 2020.5) in the IUPHAR/BPS Guide to Pharmacology Database

2020

Journal Article

Is the C3a receptor antagonist SB290157 a useful pharmacological tool?

Lee, John D., Taylor, Stephen M. and Woodruff, Trent M. (2020). Is the C3a receptor antagonist SB290157 a useful pharmacological tool?. British Journal of Pharmacology, 177 (24) bph.15264, 5677-5678. doi: 10.1111/bph.15264

Is the C3a receptor antagonist SB290157 a useful pharmacological tool?

2020

Journal Article

Absence of the C5a receptor C5aR2 worsens ischemic tissue injury by increasing C5aR1-mediated neutrophil infiltration

Wu, Mike C. L., Lee, John D., Ruitenberg, Marc J. and Woodruff, Trent M. (2020). Absence of the C5a receptor C5aR2 worsens ischemic tissue injury by increasing C5aR1-mediated neutrophil infiltration. The Journal of Immunology, 205 (10), 1-6. doi: 10.4049/jimmunol.2000778

Absence of the C5a receptor C5aR2 worsens ischemic tissue injury by increasing C5aR1-mediated neutrophil infiltration

2020

Journal Article

A validated quantitative method for the assessment of neuroprotective barrier impairment in neurodegenerative disease models

Kumar, Vinod, Lee, John D., Coulson, Elizabeth J. and Woodruff, Trent M. (2020). A validated quantitative method for the assessment of neuroprotective barrier impairment in neurodegenerative disease models. Journal of Neurochemistry, 158 (3) jnc.15119, 807-817. doi: 10.1111/jnc.15119

A validated quantitative method for the assessment of neuroprotective barrier impairment in neurodegenerative disease models

2020

Journal Article

Absence of Receptor for Advanced Glycation End Product (RAGE) Reduces Inflammation and Extends Survival in the hSOD1 Mouse Model of Amyotrophic Lateral Sclerosis

Lee, John D., McDonald, Tanya S., Fung, Jenny N. T. and Woodruff, Trent M. (2020). Absence of Receptor for Advanced Glycation End Product (RAGE) Reduces Inflammation and Extends Survival in the hSOD1 Mouse Model of Amyotrophic Lateral Sclerosis. Molecular Neurobiology, 57 (10), 4143-4155. doi: 10.1007/s12035-020-02019-9

Absence of Receptor for Advanced Glycation End Product (RAGE) Reduces Inflammation and Extends Survival in the hSOD1 Mouse Model of Amyotrophic Lateral Sclerosis

2020

Journal Article

Pharmacological characterisation of small molecule C5aR1 inhibitors in human cells reveals biased activities for signalling and function

Li, Xaria X., Lee, John D., Massey, Nicholas L., Guan, Carolyn, Robertson, Avril A. B., Clark, Richard J. and Woodruff, Trent M. (2020). Pharmacological characterisation of small molecule C5aR1 inhibitors in human cells reveals biased activities for signalling and function. Biochemical Pharmacology, 180 114156, 114156. doi: 10.1016/j.bcp.2020.114156

Pharmacological characterisation of small molecule C5aR1 inhibitors in human cells reveals biased activities for signalling and function

Funding

Current funding

  • 2022 - 2025
    Therapeutic Inhibition of Neutrophil Activity as a Disease-Modifying Treatment for Amyotrophic Lateral Sclerosis
    United States Congressionally Directed Medical Research Programs - Amyotrophic Lateral Sclerosis Research Program
    Open grant

Past funding

  • 2023 - 2024
    Therapeutic potential of targeting one of the core players of inflammation (Inflammasome) in MND
    Motor Neurone Disease Research Institute of Australia Inc Innovator Grant
    Open grant
  • 2023 - 2024
    C9orf72 dipeptide-mediated activation of microglia as a therapeutic target for MND
    Motor Neurone Disease Research Institute of Australia Inc Innovator Grant
    Open grant
  • 2022 - 2024
    Profiling monocytes in MND to assess disease progression and heterogeneity
    Cure for MND Foundation - Impact Grants
    Open grant
  • 2022 - 2023
    The role of glucagon signalling in the progression of MND
    MNDRIA Innovator Grants
    Open grant
  • 2021 - 2022
    Advancing a clinical drug targeting the complement system to treat COVID-19
    Advance Queensland Industry Research Fellowships
    Open grant
  • 2021 - 2023
    Targeting complement C5a receptor 2 as a disease-modifying treatment for motor neuron disease
    NHMRC Development Grant
    Open grant
  • 2020 - 2024
    Preclinical development of centrally active complement C3a receptor modulators as disease-modifying drugs for motor neuron disease
    Cure for MND Foundation - Drug Development Grants
    Open grant
  • 2020 - 2021
    Investigating the therapeutic inhibition of CXCR2 as a disease modifying treatment for motor neurone disease
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2019 - 2020
    Investigating the beneficial effects of complement C3aR on immune cell glucose metabolism in MND
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2019 - 2020
    Manipulation of free fatty acid receptors to tame the immune response in MND
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2018 - 2019
    Therapeutic inhibition of the terminal complement pathway as a disease-modifying treatment for motor neuron disease
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2018 - 2019
    Therapeutic testing of the clinical candidate drug PMX205 in a TDP43-based model of MND and its mechanism
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2018 - 2023
    Discovering new therapies for Motor Neuron Disease
    The University of Queensland in America, Inc
    Open grant
  • 2017 - 2018
    Therapeutic inhibition of HMGB1 to slow disease progression in MND
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2016 - 2019
    The role of C3aR signalling in slowing down the disease progression of motor neuron disease
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant

Supervision

Availability

Dr John Lee is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Available projects

  • The role of innate immune and inflammatory pathways in neurodegenerative diseases

  • The link between innate immune system and energy metabolism and its contribution to neurodegeneration

Supervision history

Current supervision

Completed supervision

Media

Enquiries

Contact Dr John Lee directly for media enquiries about their areas of expertise.

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au